Phase II trials of cardiac imaging agent BFPET underway

01/3/2013 | Yahoo

FluoroPharma said Phase II trials of its BFPET imaging agent for chronic coronary artery disease have started at Massachusetts General Hospital. In this current study, the fluorine-18-labeled tracer will be compared with Rb-82 and/or other SPECT agents such as sestamibi.

View Full Article in:

Yahoo

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ